micro-community-banner
 
  • Saved

1yr
Major Advances in Diabetes Research and Treatment Unveiled at ADA Scientific Sessions

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, highlights key themes from this year’s ADA Scientific Sessions, including significant progress in obesity treatment, type 1 diabetes, technology, health disparities, and innovation. Notable studies, such as the FLOW trial on GLP-1 receptor agonists for kidney outcomes and the Surmount OSA study on sleep apnea, were discussed.

Dr. John Buse shared insights from the Catalyst Study, revealing a high prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, potentially reshaping future screening and treatment guidelines.

  • 1yr
    Fascinating studies and gives us another armament to control DM, HTN ASVD , CKD hopefully in the near future thanks
  • Saved

1yr
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Source : https://pubmed.ncbi.nlm.nih.gov/38095657/

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Survodutide effectively reduced HbA1c and bodyweight in type 2 diabetes patients over 16 weeks, with greater bodyweight loss compared to semaglutide; gastrointestinal AEs were dose-related.

  • Saved

1yr
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies

Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies

Source : https://pubmed.ncbi.nlm.nih.gov/38183334/

Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM...

Recent advances in pharmacological management of T2DM emphasize integrated therapies focusing on cardiorenal protection, weight management, and improved glycemic control, including new dual agonists and emerging treatments.

  • Saved

1yr
Prevention of type 2 diabetes and its complications

Prevention of type 2 diabetes and its complications

Source : https://pubmed.ncbi.nlm.nih.gov/38869130/

Type 2 diabetes (T2D) represents a major medical and public health problem. The ability to prevent or delay T2D by modifying some of its risk factors has been hypothesized for...

In overweight or obese adults at high risk of developing type 2 diabetes, interventions such as weight loss strategies (including bariatric surgery), increased physical activity, and pharmacotherapy (e.g., metformin) can significantly delay onset and improve outcomes.

  • Saved

1yr
Selenium Species in Diabetes Mellitus Type 2

Selenium Species in Diabetes Mellitus Type 2

Source : https://pubmed.ncbi.nlm.nih.gov/37880477/

Selenium is an important trace element for humans and animals as it plays a key role in several major metabolic pathways. Several studies were conducted to better understand the role...

Recent studies on selenium and diabetes mellitus (DM), particularly type 2 (T2DM), reveal a complex relationship. Selenium's impact isn't linear but dose-dependent, often exhibiting a U-shaped curve influenced by chemical forms in diet or supplements. Optimal intake, considering baseline selenium levels, is crucial to mitigate diabetes risk.